CEACAM-8

CEACAM-8 Molekülinformation

Englischer Name	Non specific cross-reacting antigen 95	Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	1	Target-Alias	Non-specific cross-reacting antigen NCA-95，CGM6，Carcinoembryonic Antigen Gene Family Member 6，CD66b Antigen，NCA-95，CD67，Carcinoembryonic antigen CGM6，CD66b，CEACAM8，Carcinoembryonic Antigen Related Cell Adhesion Molecule 8，Carcinoembryonic Antigen-Related Cell Adhesion Molecule 8，CD67 Antigen，CEA Cell Adhesion Molecule 8
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Non specific cross-reacting antigen 95
Target-Alias	Non-specific cross-reacting antigen NCA-95，CGM6，Carcinoembryonic Antigen Gene Family Member 6，CD66b Antigen，NCA-95，CD67，Carcinoembryonic antigen CGM6，CD66b，CEACAM8，Carcinoembryonic Antigen Related Cell Adhesion Molecule 8，Carcinoembryonic Antigen-Related Cell Adhesion Molecule 8，CD67 Antigen，CEA Cell Adhesion Molecule 8
Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	1
Höchste Forschungs- und Entwicklungsphase	Approved

CEACAM-8 Produktliste

Attribut
Protein (2)
Produktbibliothek
Online (2)
Spezies
Human (2)
Etikett
His Tag (1)His Tag & Avi Tag (1)
Marker
Unconjugated (1)Biotin-labeled (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
CE8-H5224	Human	HEK293	Human CEACAM-8 / CD66b Protein, His Tag, low endotoxin (MALS verified)				In den Warenkorb legen
CE8-H82E9	Human	HEK293	Biotinylated Human CEACAM-8 / CD66b Protein, His,Avitag™ (SPR verified)				In den Warenkorb legen

Gesamtmenge2

CEACAM-8 Molekülhintergrund

Carcinoembryonic antigen-related cell adhesion molecule 8 (CEACAM8) is also known as CD66b (Cluster of Differentiation 66b), CD66b, CD67, CGM6, NCA-95, and is one of seven human CEACAM family members within the immunoglobulin superfamily. CEACAM family members are a set of widely expressed proteins involved in several biological functions, including cell adhesion, migration, signal transduction, and the regulation of gene expression. Abnormal overexpression and downregulation of some CEACAMs have been described in tumor cells. In humans, CEACAMs include type I transmembrane proteins (CEACAM1, CEACAM3, and CEACAM4) and GPI-linked molecules (CEACAM5 through CEACAM8). There is no human CEACAM2. CEACAM8 is a single chain, two Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. It is an activation marker for human granulocytes.

CEACAM-8 Molekülalias

CEACAM8,CD66b,CD67,CGM6,NCA-95

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
90Y-DTPA-besilesomab	TLX-66	Phase 2 Clinical	Telix Pharmaceuticals Ltd	Multiple Myeloma; Neoplasms, Plasma Cell; Plasmacytoma	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Besilesomab	99Tcm-BW250-183; TLX-66-CDx; TLX66-CDx; BW-250-183	Approved	Cis Bio International Sa	Scintimun	EU	Osteomyelitis	Cis Bio International Sa	2010-01-11	Osteomyelitis	Details